Jones et al. (2026)
- Authors: Ansley E. Jones, Zain Khan
- Institutes: Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
- Publisher: Critical Care Explorations
- Link: DOI
Summary
This research demonstrates that for many survivors of severe COVID-19, the recovery process extends far beyond the initial illness, with symptoms like fatigue and brain fog persisting for at least three years. Crucially, the study clarifies that these long-term issues are likely not caused by the same inflammatory or vascular damage markers used to assess acute severity. This finding directs the medical community to look for different biological causes and treatments for long-haul COVID rather than relying on acute-phase interventions.
What was researched?
This study investigated the long-term persistence of Post-Acute Sequelae of COVID-19 (PASC) over three years in survivors of COVID-19-related acute lung injury or acute respiratory distress syndrome. It specifically examined whether persistent symptoms were linked to biomarkers of inflammation, endothelial dysfunction, or complement activation.
Why was it researched?
Inflammation and vascular issues are known to drive severe acute COVID-19 cases during the hospitalization phase. Researchers sought to determine if these same mechanisms remain active and contribute to the prolonged symptoms experienced by survivors years after their initial discharge.
How was it researched?
The study followed a diverse cohort of survivors with a mean age of 56 years, measuring PASC symptoms—including fatigue, brain fog, and post-exertional malaise—at 15 months and 3 years post-diagnosis. Physical performance was assessed using the 6-minute walk distance and frailty scales. Blood samples were analyzed for specific inflammatory, endothelial, and complement biomarkers to find potential correlations with these long-term clinical outcomes.
What has been found?
PASC remained present in 26% of survivors at both the 15-month and 3-year follow-ups. While persistent symptoms were significantly associated with physical frailty and reduced walking capacity, they were not associated with elevated levels of the inflammatory or endothelial biomarkers typically seen in acute COVID-19. This suggests that the biological drivers of long-term PASC likely differ from the mechanisms that cause severe acute illness.
Discussion
A major strength is the long-term follow-up of a diverse cohort of severe COVID-19 survivors over three years. However, the study’s focus on a specific set of biomarkers means other pathways, such as autoantibodies or metabolic changes, were not explored. The findings highlight the complexity of PASC and the urgent need for more comprehensive multi-omic investigations.
Conclusion & Future Work
PASC continues to impact a significant portion of severe survivors for at least three years and is closely tied to physical frailty. Future research should shift away from standard acute biomarkers toward broader multi-omic approaches to uncover the true underlying mechanisms of chronic illness.